Disclosures

Al B. Benson III, MD, FACP, FASCO

Professor of Medicine, Associated Director for Cooperative Groups, Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago

Received clinical research support/data safety monitoring board from Amgen, Astellas Pharma US, Boston Scientific, Bristol Myers Squibb, Hutchmed, ITM Solucin GmbH, Merck Sharpe & Dohme, Mirati Therapeutics, St. Pharm, Syncore, Taiho Pharmaceuticals, Tyme, and Xencor

Served on scientific advisory board or as a consultant or expert witness for, Apexigen, Artemida, BioScend, Bristol Myers Squibb, Grail, HalioDx, Janssen Oncology, Merck Sharpe & Dohme, Natera, Pfizer/Hospira, Therabionic, and Xencor

Jennifer R. Brown, MD, PhD

Associate Professor of Medicine, Dana-Farber Cancer Institute, Boston

Received clinical research support/data safety monitoring board from Acerta Pharma, BeiGene, Catapult, Celgene, Eli Lilly and Company, Gilead Sciences, iOnctura, Janssen Pharmaceutica Products, MEI Pharma, SecuraBio, and TG Therapeutics

Served on scientific advisory board or as a consultant or expert witness for AbbVie, Acerta Pharma, BeiGene, Genentech, Grifols, iOnctura, Numab, Pfizer, and Pharmacyclics

Alexander Drilon, MD

Chief of Early Drug Development, Memorial Sloan Kettering Cancer Center, New York

Received honoraria and consulting fees for advisory boards from Ignyta/F. Hoffmann–La Roche/Genentech, Loxo/Bayer/Eli Lilly, TP Therapeutics, AstraZeneca, Pfizer, Blueprint Medicines, Takeda/Ariad/Millennium, Helsinn, BeiGene, BerGenBio, Hengrui Therapeutics, Exelixis, Tyra Biosciences, Verastem, MORE Health, AbbVie, 14ner/Elevation Oncology, Remedica Ltd, ArcherDX, Monopteros, Novartis, EMD Serono, Liberum, Repare RX, and Melendi

Received associated research funding paid to institution by Pfizer, Exelixis, Taiho, Teva, GlaxoSmithKline, and PharmaMar

Received research funding from Foundation Medicine; royalties from Wolters Kluwer; other from Merck, Puma, Merus, and Boehringer Ingelheim; CME honoraria from Medscape, OncLive, PeerVoice, Physicians Education Resources, Targeted Oncology, Research to Practice, Axis, Peerview Institute, Paradigm Medical Communications, WebMD, and MJH Life Sciences

David S. Ettinger, MD, FACP, FCCP

Alex Grass Professor of Oncology, The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore

Served on scientific advisory board or as a consultant or expert witness for BeyondSpring Pharmaceuticals

Thomas Flaig, MD

Professor, Medicine-Medical Oncology and Associate Dean for Clinical Research, School of Medicine, University of Colorado Cancer Center, Aurora

Received clinical research support/data safety monitoring board from Agensys, Astellas Pharma US, Bristol Myers Squibb, Genentech, Janssen Pharmaceutica Products, Merck & Co, sanofi-aventis U.S., and Seattle Genetics

Served on scientific advisory board or as a consultant or expert witness for Aurora Oncology, Janssen Pharmaceutica Products, and Seattle Genetics

Was issued patent for work done as an employee of Aurora Oncology, University of Colorado

Leo I. Gordon, MD, FACP

Abby and John Friend Professor of Cancer Research; Professor of Medicine; Co-Director, Hematologic Malignancy Program; Medical Director, John and Lillian Mathews Cellular Therapy Laboratory, Division of Hematology/Oncology, Robert H. Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine, Chicago

Received clinical research support/data safety monitoring board from Janssen Pharmaceutica Products

Served on scientific advisory board or as a consultant or expert witness for Epizyme, Janssen Pharmaceutica Products, and Ono Pharmaceuticals

William J. Gradishar, MD, FACP, FASCO

Betty Bramsen Professor of Breast Oncology and Chief, Hematology and Oncology, Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago

Received clinical research support/data safety monitoring board from Daiichi Sankyo, Genentech, Novartis, and Seattle Genetics

Served on scientific advisory board or as a consultant or expert witness for ambrx, AstraZeneca, Merck & Co, and Pfizer

Prashant Kapoor, MD

Assistant Professor of Medicine and Oncology (Division of Hematology), Mayo Clinic, Rochester, Minnesota

Served on scientific advisory board or as a consultant or expert witness for AbbVie, Cellectar, and Sanofi

Received research funding from AbbVie, Amgen, GlaxoSmithKline, Janssen, Karyopharm, Sanofi, and Takeda

Received honoraria from BeiGene, Janssen, Karyopharm, and Takeda

Shaji K. Kumar, MD

Professor of Medicine, Mayo Clinic, Rochester, Minnesota

Received clinical research support/data safety monitoring board from AbbVie, Allogene, Bristol Myers Squibb, Carsgen, GlaxoSmithKline, MedImmune, Oncopeptides, Roche Laboratories, and Takeda Pharmaceuticals North America

Served on scientific advisory board or as a consultant or expert witness for AbbVie, BeiGene, Bluebird, Bristol Myers Squibb, Epizyme, GlaxoSmithKline, GLH Pharma, Oncopeptides, Pfizer, Regeneron Pharmaceuticals, Roche Laboratories, sanofi-aventis US, Secura, Takeda Pharmaceuticals North America, and Trillium

Karl D. Lewis, MD

Associate Professor, Division of Medical Oncology, University of Colorado Denver School of Medicine

Received honoraria from Incyte and Array BioPharma

Received research funding from Roche, Merck, Incyte, Array BioPharma, Nektar, Iovance Biotherapeutics, and Bristol Myers Squibb

Served as a consultant or advisor to Array BioPharma, Merck, Roche, and Regeneron Pharmaceuticals

Rebecca Olin, MD, MS

Associate Professor, Department of Medicine (Hematology/Oncology), University of California, San Francisco

Received clinical research support from or served on data safety monitoring board from AstraZeneca Pharmaceuticals LP, Cellectis, Genentech, Mirati, Novartis Pharmaceuticals,  Spectrum Pharmaceuticals, and Takeda Pharmaceuticals North America

Served on scientific advisory board or as a consultant or expert witness for Actinium,  Janssen Pharmaceutica Products, and Oncocyte

Gregory J. Riely, MD, PhD

Vice Chair, Clinical Research, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York

Received institutional research support from Chugai, Eli Lilly and Company, Genentech, Merck & Co, Mirati, Novartis, Pfizer, and Takeda Pharmaceuticals North America

Served on scientific advisory board or as a consultant or expert witness to AstraZeneca Pharmaceuticals LP, Daiichi Sankyo, Flatiron Health, Merck & Co., Mirati, and Takeda Pharmaceuticals North America 

Sandy Srinivas, MD

Professor of Medicine/Oncology, Stanford University School of Medicine, Palo Alto, California

Received institutional research support from AstraZeneca Pharmaceuticals, Bayer HealthCare, Bristol Myers Squibb Company, Clovis Oncology, Eisai, Exelixis, Genentech, Merck & Co., Pfizer, and Seattle Genetics

Served on scientific advisory board or as a consultant or expert witness to AstraZeneca Pharmaceuticals, AVEO Pharmaceuticals, Bayer HealthCare, Bristol Myers Squibb Company, Eisai, Janssen Pharmaceutica Products, Merck & Co., Novartis Pharmaceuticals Corporation, and Seattle Genetics

Medical Writers:

The following medical writers reported no conflicts of interest.

Gavin Calabretta, BS; Jenna Carter, PhD, Vanessa A. Carter, BS; Cordi Craig, MS; Hope Craig; Celeste L. Dixon; Anna Fanelli; Joseph Fanelli; Julia Fiederlein; Lauren Harrison, MS, MD; Justine Landin, PhD; Susan London; Sarah Lynch; Victoria Kuhr, BA; Amy MacDonald, MS; Joshua Madera, MS; Margie Miller; Susan Reckling, MA; Kayci Reyer; Emily Rhodes; Joshua Swore, PhD

Sarah Campen, PharmD: Her spouse works for Johnson & Johnson/Janssen.